Aceprometazine
Appearance
This article needs additional citations for verification. (February 2020) |
![]() | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.033.315 |
Chemical and physical data | |
Formula | C19H22N2OS |
Molar mass | 326.46 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Aceprometazine (INN) is a phenothiazine derivative prescription drug with neuroleptic and anti-histamine properties It is not widely prescribed, and may be associated with drug-induced Parkinsonism.[1] It may be used in combination with meprobamate for the treatment of sleep disorders. This combination is available in France under the trade name Mepronizine.
It is structurally related to the phenothiazine derivative veterinary drug acepromazine.
Synthesis
[edit]Note: The reason for the rearrangement in the sidechain between the precursor and the product is on account of a methadone-type aziridine.
![](http://178.128.105.246/content-http-upload.wikimedia.org/wikipedia/commons/thumb/8/8f/Aceprometazine_synthesis.svg/500px-Aceprometazine_synthesis.svg.png)
2-Acetylphenothiazine [6631-94-3] (1) 2-Chloropropyldimethylamine [108-14-5] (2)
References
[edit]- ^ Blanchet PJ, Kivenko V (2016-09-23). "Drug-induced parkinsonism: diagnosis and management". Journal of Parkinsonism and Restless Legs Syndrome: 83–91. doi:10.2147/JPRLS.S99197. hdl:1866/19491.
- ^ Martin L Kantor & Tubis Samuel, U.S. patent 3,100,772 (1963 to Wyeth LLC).